MTOR and thyroid gland undifferentiated (anaplastic) carcinoma: Notably, Wagle et al. reported the emergence of an mTOR F2108L mutation in patient with anaplastic thyroid cancer bearing an inactivating TSC2 mutation, after 18 months of treatment on everolimus.